Literature DB >> 2206503

HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck.

J R Houck1, F M Sexton, G Zajdel.   

Abstract

We compared human major histocompatibility (HLA) class I and class II antigen expression on squamous cell carcinoma of the head and neck with that on normal mucosa. Frozen sections of a consecutive series of 30 squamous cell carcinomas were stained with the monoclonal antibodies W6/32 (class I) and anti-DR (class II) using an immunoperoxidase technique. Normal mucosa showed class I and class II expression in the basal layers only. Class I expression on tumors was diffuse in 87%, patchy in 10%, and scattered in 3%. Class II expression on tumors was diffuse in 20%, patchy in 53%, scattered in 20%, and absent in 7%. Patterns of expression did not correlate significantly with clinical parameters, including survival, except that class II diffuse and patchy patterns were found to correlate with more poorly differentiated tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206503     DOI: 10.1001/archotol.1990.01870100075016

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

Review 1.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells.

Authors:  J Hald; N Rasmussen; M H Claesson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

3.  HLA Antigen Profile Differences in Patients with SCC (Squamous Cell Carcinoma) In-Situ /Actinic Keratosis and Invasive SCC: Is There a Genetic Succeptibility for Invasive SCC Development?

Authors:  Mustafa Atasoy; Rana Anadolu-Braise; Ibrahim Pirim; Hasan Dogan; Mevlüt Ikbal
Journal:  Eurasian J Med       Date:  2009-12

Review 4.  T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.

Authors:  A E Albers; L Strauss; T Liao; T K Hoffmann; A M Kaufmann
Journal:  Clin Dev Immunol       Date:  2010-12-27

5.  An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.

Authors:  A R Vora; S Rodgers; A J Parker; R Start; R C Rees; A K Murray
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.